2023 ASCO | Escugen Biotechnology Announces Positive Phase I Clinical Trial Data for Trop2 ADC "ESG401"
On June 4, 2023, Escugen's ESG401 (Trop2 ADC) made a notable appearance at the 2023 ASCO meeting, presenting preliminary data from its first-in-human study in the form of a poster.
2023-06-05
